Symbolbild · KI-generiert
Pentixapharm
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. We do not have a verified market capitalisation for this company.
Company profile
Pentixapharm is a German biopharmaceutical company developing radiolabelled compounds (radioligands) for the diagnosis and treatment of cancer. The lead programme targets the CXCR4 receptor, which is overexpressed in various haematological and solid tumours. The company was established through a spin-off from the Positronpharma group.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Other sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Pentixapharm | PTP | Frankfurt | — |
| 3i | III | LSE | — |
| 5N Plus Inc. | TSX | — | |
| ALKANE RESOURCES LIMITED | ALK | ASX | — |
| ALS Limited | ALQ | ASX | — |
| AMA GROUP LIMITED | AMA | ASX | — |
| AO World | LSE | — |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.